Market overview
The global immunoadsorption columns market is worth USD 160 mn in 2026 and is forecast to reach USD 301 mn by 2036, growing at a 6.5% CAGR. Germany is the largest country market and IgG adsorbers is the largest by target segment.
| Scope | Single-use adsorber columns that remove antibodies and immune complexes from a patient's plasma in autoimmune, neurological and transplant treatment. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 150 mn |
| Value 2026 | USD 160 mn |
| Value 2036 | USD 301 mn |
| CAGR 2026-2036 | 6.5% |
| Volume 2026 | 44.7 thousand columns |
| Volume 2036 | 79.9 thousand columns |
| Average price 2026 | USD 3,589 per column |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Immunoadsorption Columns market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 160 mn |
| 2027 | USD 171 mn |
| 2028 | USD 182 mn |
| 2029 | USD 194 mn |
| 2030 | USD 206 mn |
| 2031 | USD 220 mn |
| 2032 | USD 234 mn |
| 2033 | USD 249 mn |
| 2034 | USD 266 mn |
| 2035 | USD 283 mn |
| 2036 | USD 301 mn |
Immunoadsorption Columns market segmentation
By target
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| IgG adsorbers | 44.0% | 46.9% | USD 71 mn | 7.2% |
| Antigen-specific adsorbers | 26.0% | 24.1% | USD 42 mn | 5.7% |
| Broad immunoadsorbers | 30.0% | 29.1% | USD 48 mn | 6.2% |
By indication
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Neurological disease | 34.0% | 35.8% | USD 55 mn | 7.1% |
| Rheumatic and autoimmune disease | 28.0% | 25.6% | USD 45 mn | 5.6% |
| Transplant and antibody-mediated rejection | 22.0% | 23.2% | USD 35 mn | 7.1% |
| Cardiac and other | 16.0% | 15.4% | USD 26 mn | 6.1% |
By ligand type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Protein A | 32.0% | 28.0% | USD 51 mn | 5.1% |
| Peptide | 24.0% | 28.0% | USD 39 mn | 8.2% |
| Polyclonal sheep antibody | 22.0% | 20.0% | USD 35 mn | 5.5% |
| Amino-acid ligands | 22.0% | 24.0% | USD 35 mn | 7.4% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 58.0% | 56.0% | USD 93 mn | 6.1% |
| Dialysis and apheresis centres | 30.0% | 30.0% | USD 48 mn | 6.5% |
| Specialty clinics | 12.0% | 14.0% | USD 19 mn | 8.2% |
By treatment pattern
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Acute single course | 36.0% | 34.0% | USD 58 mn | 5.9% |
| Chronic repeated courses | 44.0% | 46.0% | USD 71 mn | 7.0% |
| Pre-transplant conditioning | 20.0% | 20.0% | USD 32 mn | 6.5% |
Top 25 countries for immunoadsorption columns by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 93.5% of 2026 revenue and the 25 countries below together hold 98.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | Germany | USD 35 mn | 22.0% | USD 63 mn | 5.9% |
| 2 | Japan | USD 32 mn | 20.0% | USD 54 mn | 5.4% |
| 3 | China | USD 19 mn | 12.0% | USD 49 mn | 9.9% |
| 4 | United States | USD 16 mn | 10.0% | USD 31 mn | 6.9% |
| 5 | France | USD 13 mn | 8.0% | USD 23 mn | 6.0% |
| 6 | Italy | USD 9.6 mn | 6.0% | USD 17 mn | 6.0% |
| 7 | Austria | USD 8.0 mn | 5.0% | USD 14 mn | 5.8% |
| 8 | Spain | USD 6.4 mn | 4.0% | USD 11 mn | 6.0% |
| 9 | United Kingdom | USD 5.6 mn | 3.5% | USD 11 mn | 6.5% |
| 10 | Netherlands | USD 4.8 mn | 3.0% | USD 8.4 mn | 5.8% |
| 11 | Switzerland | USD 0.85 mn | 0.5% | USD 1.5 mn | 5.9% |
| 12 | Belgium | USD 0.64 mn | 0.4% | USD 1.1 mn | 5.7% |
| 13 | Poland | USD 0.64 mn | 0.4% | USD 1.4 mn | 8.0% |
| 14 | Turkey | USD 0.64 mn | 0.4% | USD 1.4 mn | 8.0% |
| 15 | South Korea | USD 0.64 mn | 0.4% | USD 1.4 mn | 8.0% |
| 16 | Czech Republic | USD 0.53 mn | 0.3% | USD 0.93 mn | 5.8% |
| 17 | Sweden | USD 0.53 mn | 0.3% | USD 0.93 mn | 5.8% |
| 18 | Canada | USD 0.53 mn | 0.3% | USD 0.93 mn | 5.8% |
| 19 | Australia | USD 0.53 mn | 0.3% | USD 0.93 mn | 5.8% |
| 20 | Russia | USD 0.43 mn | 0.3% | USD 0.75 mn | 5.7% |
| 21 | Brazil | USD 0.43 mn | 0.3% | USD 0.93 mn | 8.0% |
| 22 | Denmark | USD 0.43 mn | 0.3% | USD 0.75 mn | 5.7% |
| 23 | Taiwan | USD 0.43 mn | 0.3% | USD 0.75 mn | 5.7% |
| 24 | Hungary | USD 0.32 mn | 0.2% | USD 0.57 mn | 6.0% |
| 25 | Greece | USD 0.32 mn | 0.2% | USD 0.57 mn | 6.0% |
| Rest of world | USD 2.5 mn | 1.6% | USD 4.1 mn | 5.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Fresenius Medical Care
- Asahi Kasei Medical
- Kaneka
- Terumo
Group 2: Regional and specialist players
- Miltenyi Biotec
- B. Braun
- Diamed
- Aferetica
Group 3: Emerging and niche players
- Glycorex Transplantation
- Jafron Biomedical
- Zhuhai Health Biotech
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the immunoadsorption columns market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.5% is calculated from the resulting values.
The market is divided by target, by indication, by ligand type, by end user, by treatment pattern. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the immunoadsorption columns market?
The global immunoadsorption columns market is estimated at USD 150 mn in 2025 and USD 160 mn in 2026.
How fast will the immunoadsorption columns market grow?
It is forecast to reach USD 301 mn by 2036, a compound annual growth rate of 6.5% from 2026, an increase of USD 141 mn.
Which country is the largest market for immunoadsorption columns?
Germany is the largest market by revenue at USD 35 mn in 2026, 22.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 9.9% a year from 2026 to 2036.
Which immunoadsorption columns segment is largest?
In the by target split, IgG adsorbers is the largest segment with 44.0% of 2026 revenue.
Who are the leading immunoadsorption columns companies?
Global leaders include Fresenius Medical Care, Asahi Kasei Medical, Kaneka, Terumo.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Protein-Free Nutrition ModuleUSD 160 mn · 6.5% CAGR
- Canine Fungal Infection TreatmentUSD 159 mn · 5.5% CAGR
- Dermatology Cryosurgery UnitsUSD 158 mn · 5.0% CAGR
- Theranostic Workflow PlatformsUSD 156 mn · 18.0% CAGR
- AI-Powered Gait & Mobility AnalyticsUSD 151 mn · 11.0% CAGR
- Marine ToxinUSD 149 mn · 6.0% CAGR
- Fat Modular NutritionUSD 147 mn · 5.0% CAGR
- Cystic Fibrosis Nutrition ProductsUSD 145 mn · 3.5% CAGR
← Hospital-at-Home Vital Signs Monitoring Platforms Immunoassay →